Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | HTT | P42858 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL312623 | 1.00 | LMNA (0.55) | LMNAALDH1A1HTTSMN1; SMN2MAPT | |
| SCHEMBL542373 | 0.86 | TP53 (0.55) | LMNAALDH1A1HTTSMN1; SMN2MAPT | |
| SCHEMBL25667517 | 0.83 | LMNA (0.43) | LMNAALDH1A1HTTNPC1POLB | |
| SCHEMBL5839153 | 0.81 | LMNA (0.60) | LMNAALDH1A1HTTSMN1; SMN2MAPT | |
| SCHEMBL1757552 | 0.81 | LMNA (0.60) | LMNAALDH1A1HTTSMN1; SMN2MAPT | |
| SCHEMBL28629924 | 0.81 | PTPRC (0.46) | LMNAALDH1A1HTTSMN1; SMN2MAPT | |
| SCHEMBL11387105 | 0.81 | LMNA (0.42) | LMNAALDH1A1HTTNPC1POLB | |
| SCHEMBL17643692 | 0.81 | MAPT (0.57) | ALDH1A1SMN1; SMN2MAPTPOLBKMT2A | |
| SCHEMBL25667516 | 0.81 | TP53 (0.44) | LMNAALDH1A1HTTKMT2AUSP2 | |
| SCHEMBL27774615 | 0.81 | MAPT (0.57) | ALDH1A1SMN1; SMN2MAPTPOLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167058-A1 | GPX4 COMPOUNDS AND COMPOSITIONS AND METHODS OF TREATMENT USING SAME | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2023-06-01 | — | — | US | disclosed |
| US-20230167058-A1 | GPX4 COMPOUNDS AND COMPOSITIONS AND METHODS OF TREATMENT USING SAME | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2023-06-01 | — | — | US | disclosed |
| US-8093392-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-10 | — | — | US | disclosed |
| US-20110130436-A1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130436-A1 | CASPASE INHIBITORS AND USES THEREOF | CASP1, CASP3, CASP2 | LMNA 150/4885ALDH1A1 3121/4885HTT 4610/4885 |
| US-20230167058-A1 | GPX4 COMPOUNDS AND COMPOSITIONS AND METHODS OF TREATMENT USING SAME | GPX4, GPX1, AIFM2 | LMNA 3426/4885ALDH1A1 915/4885HTT 1489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.